{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:22:10Z","timestamp":1772252530170,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Managing the multisystemic symptoms of type I Gaucher Disease (GD) requires a multidisciplinary team approach that includes disease-specific treatments, as well as supportive care. This involves a range of medical specialists, general practitioners, supportive care providers, and patients. Phenotype classification and the setting of treatment goals are important for optimizing the management of type I GD, and for providing personalized care. The ability to classify disease severity using validated measurement tools allows the standardization of patient monitoring, and the measurement of disease progression and treatment response. Defining treatment goals is useful to provide a benchmark for assessing treatment response and managing the expectations of patients and their families. Although treatment goals will vary depending on disease severity, they include the stabilization, improvement or reversal (if possible) of clinical manifestations. Enzyme replacement therapy (ERT) is the standard care for patients with type I GD, but a novel substrate reduction therapy (SRT), Eliglustat, has demonstrated safety and efficacy in selected patients. To ensure that treatment goals are being achieved, regular and comprehensive follow up are necessary.<\/jats:p>","DOI":"10.3390\/diseases6030069","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T11:32:07Z","timestamp":1532604727000},"page":"69","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Importance of a Multidisciplinary Approach in the Management of a Patient with Type I Gaucher Disease"],"prefix":"10.3390","volume":"6","author":[{"given":"Miguel-\u00c1ngel","family":"Torralba-Cabeza","sequence":"first","affiliation":[{"name":"Aragon Health Research Institute (ISS Arag\u00f3n), Department of Internal Medicine, Unit of Rare Disorders, \u201cLozano Blesa\u201d University Hospital, 15th San Juan Bosco Avenue, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Olivera-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Aragon Health Research Institute (ISS Arag\u00f3n), Department of Internal Medicine, Unit of Rare Disorders, \u201cLozano Blesa\u201d University Hospital, 15th San Juan Bosco Avenue, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8796-2717","authenticated-orcid":false,"given":"Jos\u00e9-Luis","family":"Sierra-Monz\u00f3n","sequence":"additional","affiliation":[{"name":"Aragon Health Research Institute (ISS Arag\u00f3n), Department of Internal Medicine, Unit of Rare Disorders, \u201cLozano Blesa\u201d University Hospital, 15th San Juan Bosco Avenue, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI105417","article-title":"Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher\u2019s disease","volume":"45","author":"Brady","year":"1966","journal-title":"J. Clin. Investig."},{"key":"ref_2","unstructured":"Scriver, C.R., Beudet, A.L., Sly, W.S., and Valle, D. (1995). Gaucher disease. The Metabolic Basis of Inherited Disease, McGraw-Hill. [7th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0140-6736(95)90924-9","article-title":"Influence of clinician workload and patterns of treatment on survival from breast cancer","volume":"345","author":"Sainsbury","year":"1995","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/1097-0142(20010401)91:7<1231::AID-CNCR1123>3.0.CO;2-K","article-title":"The impact of a multidisciplinary breast cancer center on recommendations for patient management: The University of Pennsylvania experience","volume":"91","author":"Chang","year":"2001","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","article-title":"How I treat Gaucher Disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"ref_7","first-page":"747","article-title":"The diagnosis of the adult type of Gaucher\u2019s disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes","volume":"76","author":"Beutler","year":"1970","journal-title":"J. Lab. Clin. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.V76.3.646.646","article-title":"Misuse of marrow examination in the diagnosis of Gaucher disease","volume":"76","author":"Beutler","year":"1990","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/bcmd.2002.0535","article-title":"High prevalence of the 55-bp deletion (c.1263del55) in Exon 9 of the glucocerebrosidase gene causing misdiagnosis (for homozygous N370S (c.1226A>G) mutation) in Spanish Gaucher Disease patients","volume":"29","author":"Torralba","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1525-1470.2006.00267.x","article-title":"Autosomal recessive inheritance: Un updated review","volume":"23","author":"Mensink","year":"2006","journal-title":"Pediatr. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1016\/S0021-9258(19)39223-3","article-title":"Analyses of catalytic activity and inhibitor binding of human acid beta-glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations","volume":"265","author":"Grace","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcw002","article-title":"Residual enzymatic activity as a prognostic factor in patients with Gaucher disease type 1: Correlation with Zimran and GAUSS-I index and the severity of bone disease","volume":"109","author":"Torralba","year":"2016","journal-title":"QJM Int. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1136\/jmg.2004.028019","article-title":"Divergent phenotypes in Gaucher disease implicate the role of modifiers","volume":"42","author":"Hruska","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3324\/haematol.12379","article-title":"A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease","volume":"93","author":"Giona","year":"2008","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","article-title":"A validated disease severity scoring system for adults with type 1 Gaucher disease","volume":"12","author":"Weinreb","year":"2010","journal-title":"Genet Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollack","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2003","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bcmd.2016.10.003","article-title":"Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey","volume":"68","author":"Lau","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00431-003-1363-z","article-title":"Paediatric non-neuronopathic Gaucher disease: Recommendations for treatment and monitoring","volume":"163","author":"Baldellou","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3912\/OJIN.Vol10No01Man01","article-title":"Ten lessons in collaboration","volume":"10","author":"Gardner","year":"2005","journal-title":"Online J. Issues Nurs."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bmj.316.7133.771","article-title":"Interprofessional working and continuing medical education","volume":"316","author":"Headrick","year":"1998","journal-title":"BMJ"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.21888","article-title":"A reappraisal of Gaucher disease-diagnosis and disease management algorithms","volume":"86","author":"Mistry","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"Kuter","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","article-title":"Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States","volume":"117","author":"Balwani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.11193","article-title":"Therapy of adult Gaucher disease","volume":"92","author":"Schmitz","year":"2007","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bcpt.12977","article-title":"Relationship between glucocerebrosidase activity and clinical response to enzyme replacement therapy in patients with Gaucher Disease type I","volume":"123","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_35","unstructured":"Gorman, P. (1998). Managing Multi-Disciplinary Teams in the NHS, McGraw-Hill Education."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/6\/3\/69\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:14:32Z","timestamp":1760195672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/6\/3\/69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["diseases6030069"],"URL":"https:\/\/doi.org\/10.3390\/diseases6030069","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints201807.0089.v1","asserted-by":"object"}]},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]}}}